A blood-cancer drug cut the risk of disease progression or death by 51% in a late-stage trial

For people newly diagnosed with diffuse large B-cell lymphoma — the most common type of non-Hodgkin lymphoma — frontline options have stayed limited for years. Danish biotech Genmab and partner AbbVie reported that adding their drug Epkinly to standard treatment meaningfully extended the time patients lived without the disease worsening, cutting the risk of progression or death by 51% in a late-stage trial. The combination was generally well tolerated, and the companies will now discuss next steps with regulators worldwide.